We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases.
- Authors
Guo, Hui-Hui; Feng, Chen-Lin; Zhang, Wen-Xuan; Luo, Zhi-Gang; Zhang, Hong-Juan; Zhang, Ting-Ting; Ma, Chen; Zhan, Yun; Li, Rui; Wu, Song; Abliz, Zeper; Li, Cong; Li, Xiao-Lin; Ma, Xiao-Lei; Wang, Lu-Lu; Zheng, Wen-Sheng; Han, Yan-Xing; Jiang, Jian-Dong
- Abstract
Cardiovascular and metabolic disease (CMD) remains a main cause of premature death worldwide. Berberine (BBR), a lipid-lowering botanic compound with diversified potency against metabolic disorders, is a promising candidate for ameliorating CMD. The liver is the target of BBR so that liver-site accumulation could be important for fulfilling its therapeutic effect. In this study a rational designed micelle (CTA-Mic) consisting of α-tocopheryl hydrophobic core and on-site detachable polyethylene glycol-thiol shell is developed for effective liver deposition of BBR. The bio-distribution analysis proves that the accumulation of BBR in liver is increased by 248.8% assisted by micelles. Up-regulation of a range of energy-related genes is detectable in the HepG2 cells and in vivo. In the high fat diet-fed mice, BBR-CTA-Mic intervention remarkably improves metabolic profiles and reduces the formation of aortic arch plaque. Our results provide proof-of-concept for a liver-targeting strategy to ameliorate CMD using natural medicines facilitated by Nano-technology. Berberine has lipid-lowering effects and other metabolic benefits, but it presents with poor bioavailability. Here the authors conjugate berberine to liver-targeting nanoparticles, and show increased accumulation of berberine in the liver, improved metabolic profiles and reduced atherosclerotic plaques in mice.
- Publication
Nature Communications, 2019, Vol 10, Issue 1, pN.PAG
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-019-09852-0